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Case Report

TORCH re-activation concomitant with drug-induced hypersensitivity
syndrome shows erythema multiforme-like and vasculitis clinical
features
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Abstract
Background: Drug-induced hypersensitivity syndrome (DIHS) can be associated with cytomegalovirus (CMV)
infection, besides induced by drugs. We report a case of DIHS with prolonged atypical clinical features and
vasculitis precipitated by drug allergy, CMV, and other viral infections.
Case illustration: A 54-year-old female presented with generalized follicular erythematous papules and waxy
palmoplantar keratoderma since one month before admission. The symptoms started as a purpuric lesion on
the upper extremities, spreading as erythematous papules on the trunk with facial edema, accompanied by
fever and chronic cough. She had been previously treated with ambroxol and cephalosporin. Cutaneous drug
allergy reaction was assessed. Although in therapy with systemic corticosteroids, lesions still appeared and
became confluent, with new palpable purpura on the extremities. Histopathology showed interface dermatitis,
consisting of lymphocytes and plasma cells but lacking eosinophils, leukocytoclastic vasculitis, and numerous
dyskeratotic keratinocytes. The possibility of systemic infection was sought, and TORCH examination
suggested acute and latent infection. The patient had a positive PCR for CMV. Intravenous ganciclovir 500
mg/day for three weeks and a low dose of systemic corticosteroids led to complete cessation of skin and
pulmonary symptoms.
Discussion: The clinical and histopathological examination was consistent with erythema multiforme.
Therefore, high titer of IgM and IgG anti-CMV, and excellent response to ganciclovir supported our suspicion
of an infection-induced process. The infection might be precipitated by a drug allergy.
Conclusion: CMV-associated skin lesion could be precipitated by drug hypersensitivity, resulting in erythema
multiforme-like clinical features with vasculitis. Severe systemic involvement related to CMV reactivation. Early
anti-CMV therapy showed good improvement and reduce risk of mortality.
Keywords: cytomegalovirus, drug hypersensitivity, DIHS, vasculitis

Background

eosinophilia and systemic symptoms (DRESS) or
drug-induced hypersensitivity syndrome (DIHS).1

Drug hypersensitivity remains an important clinical
issue. It consists of various phenotypes, mainly
cutaneous adverse reactions ranging from milder
skin reactions to severe cutaneous adverse
reactions (SCARs). SCARs are life-threatening,
including Stevens-Johnson syndrome (SJS), toxic
epidermal necrolysis (TEN), and drug reaction with

DIHS is associated with the reactivation of herpes
viruses, especially human herpesvirus 6 (HHV-6)
and cytomegalovirus (CMV). DIHS tends to have a
relatively later onset than other types of drug
eruptions, approximately 2–8 weeks after the
administration of the causative drug. DIHS is
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usually associated with only a limited number of
drugs, including carbamazepine, phenytoin,
phenobarbital, lamotrigine, dapsone, mexiletine,
salazosulfapyridine, allopurinol, and minocycline.1
Cytomegalovirus (CMV), a member of the
Herpesviridae family, is an opportunistic infection
with a typically benign course in the
immunocompetent person but could have a severe
course in the immunocompromised one. CMV
infection usually affects visceral organs, mostly the
respiratory and gastrointestinal tract. Cutaneous
manifestations caused by CMV are rarely reported
and have various forms, such as morbilliform rash,
petechiae, purpura, and vasculitis.2,3 Vasculitis
associated with CMV seems to be a more fulminant
disease with fatal outcomes in the majority of
cases.2-4 Here, we present a case of DIHS
triggered by cytomegalovirus coexisting with other
viral infections (TORCH) with atypical features of
targetoid lesions, vasculitis, and ulceration.
The prognosis of DIHS/DRESS is highly variable
and unpredictable either short-term or long-term.
The cause of mortality in DIHS/DRESS have been
described in previous studies mainly due to
complications such as myocarditis, Pneumocystis
jirovecii pneumonia, gastrointestinal bleeding and
sepsis.5

Case Illustration
A 54-year-old female came to the outpatient clinic
with a chief complaint of erythematous itchy
patches on the face, neck, trunk, hand, and red
dots on her extremities in the last 4 weeks before
admission (figure 1). The lesions began with a
single red dot on her right arm and had a
generalized spreading in several days. She also
complained of fever and chronic sign of respiratory
infection, previously treated with cephalosporin,
paracetamol, and ambroxol ten day before the
lesion appeared. She was diagnosed with drug
eruption in a previous hospital and treated with
intravenous
steroids
with
no
significant
improvement. The erythematous plaques and
petechial lesions worsened. No history of contact
irritant or allergen.
On physical examination, we found facial edema
and fever 39oC with multiple and confluent
erythematous plaques on the upper and lower part
of the body, with vasculitis lesions on both legs.
There were several atypical/targetoid lesions on
her legs (figure 2) and hyperkeratosis of
palmoplantar (figure 4). We also found multiple
ulcerations in the perianal region with a kissing-like
appearance (figure 3).
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Laboratory abnormalities include leukocytosis with
eosinophilia (2.6 x 109/L) and elevation of blood
urea and creatinine level three times more than
normal, supporting drug-induced hypersensitivity
syndrome (DIHS). She also had elevated blood
glucose, electrolyte imbalance, and high lactate
dehydrogenase level. Other differential diagnoses
at that time were erythema multiforme, secondary
syphilis, and Rowell syndrome. The patient
underwent skin biopsy and other laboratory
examinations to exclude other differential
diagnoses.
Histopathology from the erythematous plaque on
the abdominal area and purpuric papules on the
lower leg showed orthokeratosis with focal
parakeratosis, scattered necrotic keratinocytes,
and heavy infiltrate consisting of lymphocytes,
plasma cells, but lacking eosinophils in the dermoepidermal junction (interface dermatitis). There
was also vascular damage with neutrophil
infiltration, nuclear dust, and extravasated
erythrocytes (figure 5).
There was no reactivity on the syphilis serological
test. ANA was positive with titer 1/100, and C3 and
C4 complement levels were normal. There was
reactivity of anti-toxoplasma IgM, with a cut-off
index (COI) of 1, anti-rubella IgG (162.3 IU/mL),
anti-CMV IgM (COI 6.5), anti-CMV IgG (2242
U/mL), anti-HSV 1 IgM (COI 3.45), anti-HSV 1 IgG
(COI 2.41), anti-HSV 2 IgM (COI 1.44), and antiHSV 2 IgG (COI 1.33). HBsAg and anti-HCV tests
were negative. HIV test results were negative, but
CD4+ and CD3+ cell counts were low (175 and 442
cells/µL, respectively).
The diagnosis of DIHS was sought, following a 6score with the scoring system for RegiSCAR
(definite for DIHS), which consisted of the need for
hospitalization, reaction suspected to be drugrelated, acute skin rash, fever, eosinophilia, and
renal involvement. We administered 1 mg/BW oral
corticosteroid, but there was no significant
improvement after seven days of administration.
Meanwhile, within several days of admission, the
erythematous plaques began to spread all over the
body with some areas of normal skin. Petechiae
and
purpuras
slowly
transformed
into
erythematous plaques.
Clinicopathology and laboratory findings led us to
the diagnosis of vasculitis caused by drug allergy
coexisting with other virus infections. Drugs
previously consumed by the patient could
precipitate skin abnormalities. The targetoid
lesions on the legs, kissing-like ulcers in the
genital, and the HSV-1 and HSV-2 antibody
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reactivity also supported the diagnosis of erythema
multiforme and genital herpes.

Figure 1. Erythematous plaques on the upper and lower part of the body, with vasculitis lesions on both legs

Figure 2. Target-like/atypic lesions on lower legs (red circle)
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Figure 3. Multiple perianal ulcers

Figure 4. Hyperkeratosis of palmoplantar

Figure 5. Histopathology interpretation A. Hematoxylin-eosin (HE) 100X. Orthokeratosis with focal
parakeratosis; scattered necrotic keratinocytes and heavy lymphocytic infiltrate in the dermo-epidermal
junction (interface dermatitis) B. HE 400X. Vascular damage, with neutrophil infiltration, nuclear dust and
extravasated erythrocytes C-D. (HE, 400X). Exocytosis of lymphocytes and extravasated erythrocytes
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Figure 6. Three months after treatment; multiple hyperpigmentation macules, discrete
The patient also had a cough and dyspnea for
several days before admission. Chest X-rays
showed diffuse infiltrate on bilateral lower lungs,
suggesting interstitial lung disease hypersensitivity
pneumonitis. Thorax CT scan revealed no specific
features for CMV pneumonitis. She was first
diagnosed with community-acquired pneumonia by
the respirology division. Three weeks after
admission, the cough and dyspnea worsened, and
she experienced acute respiratory distress
syndrome. Further evaluation of the pulmonary
condition led to the diagnosis of CMV pneumonitis.
We started administering ganciclovir 500 mg/day
for 21 days. Oral corticosteroid was also continued
alongside antiviral administration. No new lesion
appeared and improvements in skin lesions were
seen within the first week, and the pulmonary
symptoms also improved in 3 weeks after antiviral
administration. Three months after treatment; skin
lesion resolve to multiple hyperpigmentation
macules, discrete (Figure 6)

Discussion
Cutaneous cytomegalovirus is rarely reported due
to difficulty in identifying the clinical and
pathological features. The most common
dermatologic manifestations of CMV are perianal
and oral ulcers, but many other dermatological
manifestations can complicate the diagnosis. A
review by Drozd, et al.2 mentioned that cutaneous
CMV could manifest as morbilliform rash,
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petechiae, purpura, plaques, vesicles, bullae,
erosions, erythema, nodules, papules, edema,
vasculitis, and pustules. In this review, four patients
were diagnosed with CMV reactivation after druginduced hypersensitivity syndrome (DIHS),
resulting in cutaneous manifestations that resolved
only when the CMV infection was treated. The
complete mechanism has not been elucidated, but
there is evidence of the reactivation of latent CMV
by DIHS.6 The clinical presentation ranges from
ulcerated erythematous plaques and papules to
widespread, dark-erythema, and purpura. It has
been proposed that the drug in DIHS causes
expansion of the regulatory T-cell population,
which reactivates latent herpes viruses. Tissue
damage occurs due to activated CD8+ T-cells that
target viral antigens.2-3
Petechiae is a rare cutaneous manifestation of
CMV, as seen in our patient. Cases of CMV-related
petechiae were initially diagnosed as secondary
immune thrombocytopenic purpura (ITP) or
microangiopathy-related CMV, which were
diagnosed after refractory treatment for primary
ITP.2 In this patient, skin lesions started as
petechiae,
which
then
transformed
into
erythematous papules and plaques, typical for
vasculitis lesions.
The appearance of erythematous plaques with
palmoplantar keratoderma in our patient is
questionable because it does not fit DIHS and the
rapid onset of lesions following two days of
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exposure to offending drugs. Petechiae, as the first
emerging lesion preceding almost all of the lesions,
was distinctive. The severity of lesions also
increased with the consumption of certain drugs,
indicating that drug hypersensitivity induced the
latent virus to reactivate. Interestingly, not only
CMV infection manifested by vasculitis appears,
but also the presence of erythema multiforme-like
lesions and perianal ulcers. The characteristic
lesion of erythema multiforme in the form of a target
lesion with 3 ring zones was not found in the
patient.
The reactivity of CMV, HSV-1 and 2, toxoplasma,
and rubella antibodies could also raise suspicion of
multiple viral reactivations by drug allergy.
Reactivation of CMV has been implicated in driving
DIHS through viral T-cell expansion and drugantigen cross-reactivity.7 In an analysis of
peripheral blood T cells (CD4 and CD8) in 40
patients with DIHS due to allopurinol,
sulfonamides, and carbamazepine, over 70% of
patients demonstrated EBV, HHV6, or HHV7
reactivation. The activation of CD8 was present in
all patients in the skin, liver, and lungs, and tumor
necrosis factor-α and interferon-γ levels correlated
with the severity of systemic involvement. Drugrelated viral reactivation and the ensuing immune
response to viral epitopes explain how multi-organ
symptoms occur long after discontinuation the
culprit drug.8 The mortality of DIHS approximately
10% and often related to unrecognized myocarditis
and cytomegalovirus complications, with longerterm consequences that contribute to morbidity.9
The histopathological results revealed patterns
corresponding with interface dermatitis, as usually
seen in erythema multiforme. This was the starting
point that we looked for the probability of infection
as the triggering factor in our patient. This
suspicion was also supported by the fact that
cessation of a certain drug (i.e.insulin) followed by
systemic corticosteroids failed to give satisfactory
results. Thus, leucocytoclastic vasculitis was
thought to result from the same process, with a viral
infection as a possibility.
The histological features that could lead to CMVskin infection are intranuclear inclusions
surrounded by a clear halo (owl’s eye inclusions),
dermal vessel dilatation, and prominent
perivascular neutrophilic infiltration. Signs of
infection were not observed in the epidermis or in
the eccrine structures as previously reported.3
Our patient’s low CD4+ cell counts indicated an
immunocompromised condition, although the HIV
test
results
were
negative.
This
immunocompromised condition could lead to the
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appearance of all TORCH infections. Treatment of
CMV is often simple, yet making the correct
diagnosis often needs prolonged time and
complicates the management. Early detection is
important to prevent mortality, especially in the
immunocompromised. In our patient, although it
was slow, skin lesions were improved after
administration of ganciclovir, supporting the
diagnosis of cutaneous-related CMV infection.
Previous studies indicated that CMV reactivation
are the cause of fatal complications occurring in the
late stage of DIHS, could be preventable with antiCMV therapy. In support of this possibility, a delay
in initiating anti-CMV therapy after the first
detection of CMV reactivation was likely to reduce
efficacy.10

Conclusion
As seen in our patient, CMV-associated skin lesion
could be precipitated by drug hypersensitivity
syndrome, resulting in a prolonged atypical
vasculitis. TORCH examination seems to be a
useful screening test for such infection. Excellent
response with ganciclovir and oral corticosteroid
administration indicated that the cytomegalovirus
infection precipitated by drug allergy was the
nature of this disease.
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